- Organon & Co OGN has reported Q3 sales of $1.6 billion, down 1% Y/Y, slightly higher than the consensus of $1.58 billion.
- Women's Health declined 10% to $381 million, driven primarily by a decline in Nuvaring (etonogestrel/ethinyl estradiol vaginal ring), impacted by generic competition Nexplanon (etonogestrel implant), which declined 8%.
- Biosimilars revenue grew 41% to $140 million, driven by continued demand growth in the US for Renflexis. The portfolio also benefited from the continued uptake of Ontruzant.
- The adjusted gross margin declined to 64.9% from 68.6%, and the EBITDA margin contracted from 46.6% to 39.8%.
- Adjusted EPS declined 30% to $1.67, beating the consensus of $1.44.
- Related Link: Merck Completes Women's Health Organon Spinoff.
- Guidance: Organon tightened its sales guidance to $6.2 billion - $6.3 billion, compared to prior guidance of $6.1 billion - $6.4 billion.
- M&A: Organon also announced to acquire Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women's health.
- Deal consideration includes a $75 million upfront payment, development & regulatory milestone of $270 million, and commercial milestones payments of up to $600 million.
- Price Action: OGN shares are trading lower by 4.30% at $35.06 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in